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Objective: Obesity is an established risk factor for kidney damage. In this study, we
explored the long-term association of changes in body mass index (BMI) over time with
incident chronic kidney disease (CKD).
Methods: For this analysis, 5,393 middle-aged adults without comorbidities in
the Korean Genome and Epidemiology Study (KoGES) were included. Group-based
trajectory modeling was used to determine the patterns of BMI change (decreasing,
stable, and increasing BMI) between baseline and year 4. The primary outcome was
the subsequent development of CKD from year 4. A multivariable Cox proportional
hazards model was constructed to determine the risk of incident CKD according to
BMI trajectories.
Results: During 55,327 person-years, incident CKD occurred in 354 (6.5%) participants;
6.0, 6.1, and 7.8 per 1,000 person-years across the trajectories, respectively (P= 0.005).
In the multivariable-adjusted Cox proportional hazards model, the increasing BMI
trajectory was associated with a 1.4-fold [hazard ratio (HR), 1.41; 95% CI, 1.06–1.87]
a higher risk of incident CKD compared with stable BMI trajectory. This association was
stronger for overweight and obese individuals. The HRs for CKD development in these
two groups were 1.6 (95% CI, 1.06–1.87) and 2.2 (95% CI, 1.40–3.48), respectively.
While the increasing BMI group was gaining weight, there were concomitant increases in
blood pressure, insulin resistance, serum concentrations of total cholesterol, triglyceride,
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and high-sensitivity C-reactive protein (hs-CRP), and fat mass, but high-density
lipoprotein (HDL)-cholesterol level and muscle-to-fat (MF) ratio decreased.
Conclusion: Weight gain is associated with an increased risk of incident CKD in healthy
adults. This association is attributed to worsening metabolic profiles and increasing
fat mass.
Keywords: body mass index, group-based trajectory modeling, chronic kidney disease, metabolic profiles, body
composition
INTRODUCTION
Over the past 5 decades, obesity has become a serious health
concern (1). The estimated direct and indirect costs associated
with obesity among adults account for 20.6% of the United States
healthcare expenditure or US$209 billion (2). More importantly,
the prevalence of obesity is expected to increase by 40%
worldwide in the next decade (3). Obese individuals are highly
likely to have metabolic disturbances, including hypertension,
diabetes, dyslipidemia, and inflammation, and obesity itself
constitutes a major component of metabolic syndrome (4–7).
In addition, subjects with metabolic syndrome have a 2.6-fold
higher risk of incident chronic kidney disease (CKD) than
healthy individuals (8). Interestingly, the prevalence of these
comorbid conditions has increased concomitantly with obesity
(9). A high body mass index (BMI) is a major risk factor
for adverse renal outcomes, including a decreased estimated
glomerular filtration rate (eGFR), development of CKD, and
progression to end-stage kidney disease (10–12). Obesity-
induced glomerular hyperfiltration, hypertension, and metabolic
disturbances underlie the negative effects of obesity on the
kidney, all of which can cause filtration barrier injuries and
eventually, proteinuria (13–16).
Major shortcomings of studies regarding obesity include
the use of cross-sectional analysis, simple definition for the
changes in body weight during fixed time frames, and failure
to account for dynamic changes in weight over various time
periods. In addition, the association of weight changes with the
new development of CKD has seldom been tested in healthy
adults. Thus, we aimed to explore the pure association between
changes in weight and incident CKD amongmiddle-aged Korean
individuals without medical disease according to three different
trends of BMI over 11 years using the database from the
large-scale prospective cohort study. We further evaluated the
association between trends in BMI and changes in metabolic
profiles and body composition.
MATERIALS AND METHODS
Study Design and Population
The Korean Genome and Epidemiology Study (KoGES) is
a consortium project launched in 2001 by Korea’s National
Research Institute of Health, Centers for Disease Control and
Prevention, and theMinistry of Health andWelfare, and includes
six prospective cohort studies categorized into population-based
and gene-environment model studies. The rationale, design,
methods, and protocol summary of the KoGES are described in
detail elsewhere (17). Briefly, 10,030 Korean adults aged between
40 and 69 years, comprising 5,012 (49.9%) residents from Ansan
(urban area) and 5,018 (50.1%) residents from Ansung (rural
area) were enrolled between 2001 and 2002. All participants
provided informed consent. They underwent government-
sponsored medical health check-ups and undertook different
surveys at the baseline. Serial follow-up assessments of the
biochemical data of the participants were performed biennially
from 2001 to 2014. KoGES was conducted in accordance with the
Declaration of Helsinki and approved by the Institutional Review
Board of Yonsei University Health System’s Clinical Trial Center
(approval number: 4-2016-0100).
The participants who had attended < 2 clinic visits
(n = 965) were excluded. We also excluded 2,797 participants
with BMI < 18.5 kg/m2 (n = 246), prior kidney disease
or baseline eGFRs of < 60 ml/min/1.73 m2 (n = 342),
prior hypertension or use of blood pressure-lowering agents
(n = 1,304), history of diabetes or use of blood glucose-lowering
agents (n= 447), history of dyslipidemia or use of lipid-lowering
agents (n = 226), prior cardiovascular events (n = 123), or
albuminuria (n = 109). We also excluded individuals with
missing variables, development of renal outcome within the
third visit, and loss of follow-up within 4 years (n = 875).
Consequently, 5,393 healthy participants who did not have a
medical disease at the baseline were included in the present study
(Supplementary Figure 1).
Data Collection
A standardized self-administered questionnaire was used to
collect demographic data of each participant (age, sex, medical
history, medication use, alcohol consumption habit, smoking
habit, level of education, and monthly income). Smoking and
alcohol consumption habits were divided into two categories
as never or ever (including current or former). The education
level was classified into three categories: primary, middle or high
secondary, and post-secondary. Income per month was divided
into four categories; <$850 per month; $850 to $1,700 per
month; and >$1,700 per month. Trained nurses measured the
BP levels using a standard mercury sphygmomanometer while
the participants were seated. Height was measured to the nearest
0.1 cm with a stadiometer, while the participants stood barefoot.
Weight was measured while the participants wore light clothes
and no shoes. The BMI was calculated by dividing the initial
weight (kg) by height squared (m2), and it was categorized as
normal weight (BMI 18.5–22.9 kg/m2), overweight (BMI 23–24.9
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kg/m2), or obese (BMI ≥ 25 kg/m2) using the International
Association for the Study of Obesity, International Obesity Task
Force (2000), and Committee of Clinical Practice Guidelines
and Korean Society for the Study of Obesity (18, 19). Blood
and urine samples obtained after an 8 h fast were transported
to Seoul Clinical Laboratories, Seoul, Republic of Korea, within
24 h of sampling to minimize laboratory errors, and the
hemoglobin, blood urea nitrogen, creatinine, total cholesterol,
triglyceride, and high-density lipoprotein-cholesterol (HDL-C)
were measured using Hitachi 747 chemistry analyzer (Hitachi
Ltd, Tokyo, Japan). High-sensitivity C-reactive protein (hs-CRP)
levels were measured by immunoradiometric assay (ADVIA
1650, Bayer Diagnostics, Tarrytown, NY, USA). The low-density
lipoprotein cholesterol (LDL-C) levels were calculated using the
following formula: [total cholesterol (mg/dl)—HDL-C (mg/dl)—
triglyceride (mg/dl)/5]. The serum insulin concentrations were
measured by radioimmunoassay (LINCO kit, St Charles, MO,
USA). Insulin resistance was assessed with the homeostasis
model assessment of insulin resistance (HOMA-IR) equation
[fasting insulin (µIU/ml) × fasting glucose (mg/dl)/405] (20).
A dipstick urine test was used for the detection of albuminuria
or microscopic hematuria. The serum creatinine level was
measured using the Jaffe method throughout the study period.
Thus, we converted non-isotope dilution-mass spectrometry
(IDMS) creatinine to IDMS creatinine (21, 22). Then, eGFRs
were calculated using the CKD-Epidemiology Collaboration
equation (22). The laboratory parameters were measured
at the baseline and every 2 years thereafter. Trained staff
performed all the measurements, including the anthropometric
parameter measurements.
Assessment of Body Composition
Body composition was assessed using multi-frequency
bioelectrical impedance analysis (BIA; InBody 3.0, Biospace,
Seoul, Korea). Detailed information for BIA is described
elsewhere (23). The muscle mass was expressed as the muscle
mass index (MMI, muscle mass/height2). The fat mass was
expressed as the fat mass index (FMI, fat mass/height2). The
muscle-to-fat (MF) ratio was defined as MMI/FMI.
Exposure and the Primary Endpoint
This study’s main exposure is changes in BMI over time. The
primary outcome was incident CKD, which was defined as two
consecutive eGFRs < 60 ml/min/1.73 m2 that occurred during
the follow-up period, the first of which was designated as the
endpoint. To evaluate the association of early BMI changes
with the subsequent CKD development that occurred at a
later time point, we analyzed only the adverse kidney events
FIGURE 1 | Trajectory modeling identified three distinct BMI trajectory groups. (A) The primary analysis derived BMI trajectory groups using the first 4-year BMI
measurements. (B) The slopes of BMI trajectories were significantly different across the three groups (P-value for group × Time interaction < 0.001). BMI, body mass
index.
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TABLE 1 | Baseline characteristics of the trajectories of changes in the body mass index (BMI) groups.






Participants, No. (%) 5,393 874 3,706 813
Age, mean (SD), years 50.8 (8.5) 50.3 (8.28) 50.9 (8.5) 51.1 (8.6) 0.11
Sex, No. (%) <0.001
Men 2,636 (48.9) 377 (43.1) 1,894 (51.1) 365 (44.9)
Women 2,757 (51.1) 497 (56.9) 1,812 (48.9) 448 (55.1)
Residence, No. (%) <0.001
Ansung 2,715 (50.3) 342 (39.1) 1,863 (50.3) 510 (62.7)
Ansan 2,678 (49.7) 532 (60.9) 1,843 (49.7) 303 (37.3)
Smoking habit, No. (%) <0.001
Never 3,155 (58.5) 552 (63.2) 2,130 (57.5) 473 (58.2)
Ever 2,238 (41.5) 322 (36.8) 1,576 (42.5) 340 (41.8)
Alcohol consumption habit, No. (%) 0.10
Never 2,408 (44.7) 405 (46.3) 1,612 (43.5) 391 (48.1)
Ever 2,985 (55.4) 469 (53.7) 2,094 (56.5) 422 (51.9)
Education level, No. (%) <0.001
Primary 1,593 (29.8) 231 (26.6) 1,069 (29.1) 293 (36.1)
Middle or High secondary 3,030 (56.6) 508 (58.6) 2,067 (56.2) 455 (56.1)
Post-secondary 731 (13.7) 128 (14.8) 540 (14.7) 63 (7.8)
Household income per month, No. (%) <0.001
<850 $ 3,292 (62.2) 708 (61.4) 2,205 (60.6) 559 (70.3)
850–1,700 $ 1,585 (30.0) 264 (30.7) 1,122 (30.9) 199 (25.0)
>1,700 $ 415 (7.8) 68 (7.9) 309 (8.5) 38 (4.8)
Follow-up duration, mean (SD), years 10.2 (2.6) 10.1 (2.6) 10.3 (2.5) 10.1 (2.8) 0.04
Baseline BMI, mean (SD), kg/m² 24.3 (3.1) 25.8 (3.2) 24.1 (2.9) 23.5 (3.1) <0.001
Changes in BMIa, mean (SD), % −0.3 (5.4) −7.5 (3.4) −0.1 (2.7) 7.6 (3.9) <0.001
Baseline BMI category, No. (%) <0.001
Normal weight (18.5–22.9 kg/m2 ) 1,829 (34.0) 159 (18.2) 1,301 (35.1) 369 (45.3)
Overweight (23.0–24.9 kg/m2) 1,467 (27.2) 186 (21.3) 1,075 (29.0) 206 (25.3)
Obese (≥25.0 kg/m2 ) 2,097 (38.9) 529 (60.5) 1,330 (35.9) 238 (29.3)
Blood pressures, mean (SD)
Systolic, mmHg 118.1 (16.3) 121.0 (17.6) 117.6 (16.0) 117.1 (15.9) <0.001
Diastolic, mmHg 78.8 (10.8) 80.8 (11.1) 78.6 (10.7) 77.5 (10.4) <0.001
MAP, mmHg 91.3 (12.0) 94.3 (12.6) 91.6 (11.9) 90.7 (11.6) <0.001
Laboratory results, mean (SD)
Hemoglobin, g/dL 13.5 (1.5) 13.5 (1.6) 13.6 (1.5) 13.4 (1.5) 0.01
Blood urea nitrogen, mg/dL 14.1 (3.5) 14.0 (3.4) 14.1 (3.5) 14.2 (3.5) 0.72
Creatinine, mg/dL 0.8 (0.1) 0.8 (0.1) 0.8 (0.1) 0.8 (0.1) 0.90
eGFR, mL/min per 1.73 m2 93.9 (12.7) 93.2 (12.9) 93.8 (12.7) 95.1 (12.2) 0.007
Fasting glucose, mg/dL 89.4 (15.6) 91.7 (16.8) 89.1 (14.8) 88.7 (17.1) <0.001
HbA1c, % 5.6 (0.5) 5.6 (0.6) 5.5 (0.5) 5.6 (0.6) <0.001
HOMA-IRb 1.6 (1.1) 1.8 (1.1) 1.6 (1.2) 1.5 (0.8) <0.001
Albumin, g/dL 4.2 (0.3) 4.2 (0.3) 4.2 (0.3) 4.1 (0.2) <0.001
hs-CRPc, median (IQR), mg/L 1.3 (0.6–2.3) 1.5 (0.7–2.5) 1.3 (0.6–2.3) 1.2 (0.5–2.1) <0.001
Lipid profiles, mean (SD)
Total cholesterol, mg/dL 188.6 (34.0) 193.8 (35.4) 188.6 (33.6) 182.8 (33.8) <0.001
Triglyceride, mg/dL 153.6 (98.1) 165.7 (106.1) 153.4 (99.9) 141.8 (77.0) <0.001
HDL-cholesterol, mg/dL 45.1 (9.9) 44.2 (9.5) 45.2 (9.9) 46.1 (10.1) <0.001
LDL-cholesterol, mg/dL 116.9 (33.1) 120.8 (33.9) 116.9 (32.8) 112.5 (32.6) <0.001
(Continued)
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MMI (muscle mass/height2 ) 43.8 (8.0) 44.4 (7.9) 43.8 (8.0) 42.4 (7.6) <0.001
FMI (fat mass/height2 ) 16.5 (5.3) 19.2 (5.6) 17.2 (4.9) 15.0 (5.3) <0.001
MF ratio (MMI/FMI) 2.6 (1.1) 2.3 (1.0) 2.5 (1.1) 3.0 (1.3) <0.001
Variables for categorical variables are given as the number (percentage) of participants unless otherwise indicated.
To convert serum creatinine to micromoles per liter, multiply by 88.4; to convert to urea nitrogen to millimoles per liter, multiply by 0.357; to convert glucose to millimoles per liter, multiply
by 0.0555; to convert total, HDL, and LDL cholesterol to millimoles per liter, multiply by 0.0259; and to convert triglycerides to millimoles per liter, multiply by 0.0113.
aChanges in BMI were calculated as the percent BMI changes between the baseline and the third visit.
bHOMA-IR was calculated according to the formula; fasting insulin (µIU/ml) × fasting glucose (mg/dL)/405.
cVariables were compared by the Kruskal-Wallis method.
BMI, body mass index; MAP, mean arterial pressure; eGFR, estimated glomerular filtration rate; HOMA-IR, homeostasis model assessment for insulin resistance; hs-CRP, high-sensitivity
C-reactive protein; HDL, high-density lipoprotein; LDL, low-density lipoprotein; MMI, muscle mass index; FMI, fat mass index; MF, muscle-to-fat.
TABLE 2 | Hazard ratios for the incident chronic kidney disease according to the body mass index trajectory groups.
Events Person-years Incidence rate
1,000 person-years
Delta BMI (%) Model 1 Model 2 Model 3 Model 4
Decreasing 54 8,909 6.0 −5.6 (−8.8 to−2.0) 0.98 (0.72–1.31) 1.0 (0.77–1.40) 0.91 (0.67–1.24) 0.89 (0.65–1.20)
Stable 236 38,227 6.1 −0.2 (−0.5 to 0.2) Reference Reference Reference Reference
Increasing 64 8,191 7.8 5.6 (1.9 to 9.3) 1.27 (0.96–1.68) 1.30 (0.99–1.78) 1.39 (1.04–1.86) 1.45 (1.08–1.94)
Model 1: a crude analysis without adjustment.
Model 2: an adjusted model including age and sex.
Model 3: Model 2 plus the area of residence, smoking habit, alcohol consumption habits, income, education level, body mass index, mean arterial pressure, hemoglobin, fasting glucose,
and estimated glomerular filtration rate.
Model 4: Model 2 plus high-density lipoprotein-cholesterol, triglyceride, and high-sensitive C-reactive protein.
CKD, chronic kidney disease; BMI, body mass index; HRs, hazard ratios; CI, confidence interval.
that occurred after 4 years of the BMI trajectory assessment
period (Figure 1A).
Trajectory Analysis
To determine BMI trajectories, we used group-based trajectory
modeling (GBTM) (24–26). It assumes that the participants are
composed of multiple groups having trajectories that follow
the same development course on the outcome of interest.
According to these assumptions, time-dependent covariates
explain variation in the average trajectory within each group.
In this study, we used three BMI measurements at the
baseline, and years 2 and 4. The heterogeneity of the slopes
of BMI trajectory groups was tested using the “TRAJTEST”
macro. Model fit was assessed with the following methods:
(1) the Bayesian Information Criterion (BIC), (2) the number
of participants in each trajectory (>5% overall population),
and (3) average probability of final group membership across
the trajectory groups to assess the discrimination power of
the individual model. We constructed models with different
numbers of trajectory groups and different forms of potential
trajectories (linear, quadratic, or cubic). We started a model
with 3, 4, and 5 trajectories and then evaluated different
functional forms to the enhanced model fit and calculated
the posterior probabilities for each number of participants
in several trajectory groups to test the discrimination power
of the model (Supplementary Table 1). When the number of
trajectories was ≥4, the BIC was decreased, and the number of
participants in each trajectory was also decreased, resulting in
less discrimination power across the trajectory groups. Finally,
we identified three BMI trajectory groups according to the visual
appearance and clinically meaningful BMI trend: decreasing BMI
(slope of BMI per year (%) = −0.47, 95% CI −0.46 to −0.48;
p < 0.001), stable BMI (slope = 0.001, 95% CI 0.001–0.002;
P = 0.014), and increasing BMI (slope = 0.50, 95% CI 0.49–
0.50; p < 0.001) (Figure 1B). The BMI slopes were significantly
different across the three groups (P-value for group × time
interaction <0.001).
Statistical Analysis
The continuous variables are expressed as the means and SDs or
as the medians with interquartile ranges (IQRs). The categorical
variables are expressed as numbers and percentages. The baseline
characteristics of the participants who were grouped according
to different trajectories were compared using an ANOVA for
continuous variables and the chi-square test for categorical
variables. Person-years of follow-up were calculated from the
baseline until the date of incident CKD or the last visit. The
Kaplan-Meier analysis and log-rank test were used to estimate
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FIGURE 2 | Restrict cubic spline analysis for risk of incident chronic kidney
disease (CKD) by changes in BMI (%). HR was expressed after adjustment of
covariates, including age, sex, the area of residence, smoking, alcohol
consumption habit, income, education levels, body mass index, mean arterial
pressure, hemoglobin, albumin, fasting glucose, estimated glomerular filtration
rate, high-density lipoprotein-cholesterol, triglyceride, and high-sensitive
C-reactive protein. BMI, body mass index; CKD, chronic kidney disease; CI,
confidence interval.
the cumulative renal survival rates. Survival time was defined as
the time interval between enrollment and the onset of outcome
events. Multivariable Cox proportional hazards models were
constructed to assess the associations between the trajectories of
BMI and incident CKD with three adjustment levels. Violation
of the proportional hazards assumption was tested by inspection
of log [–log (survival)] curves. Model 1 represented the crude
hazard ratios (HRs) without adjustments. Model 2 included
baseline age and sex. Model 3 incorporated the area of residence,
smoking habits, alcohol consumption habits, income, education
level, BMI, mean arterial pressure (MAP), hemoglobin, glucose,
and eGFR. Model 4 was constructed after further adjustments
to include HDL-C, triglyceride, and hs-CRP levels. The results
from multivariable Cox models are presented as the HRs and
95% CIs.
In sensitivity analysis, we examined the association of three
4 year BMI trajectories with different outcome assessment
periods (4–8 years). We further tested the association between
changes in BMI and incident CKD among prespecified subgroups
by sex (male or female), age (<50 or ≥50 years), smoking
status, alcohol consumption habit, and baseline BMI (18.5–
22.9, 23.-24.9, or ≥25. kg/m2). We also performed additional
sensitivity analysis after excluding 534 subjects with isolated
microscopic hematuria. Restricted cubic splines were used
to reveal the association between percent BMI changes as
continuous variables and risk of incident CKD. The rate
of eGFR decline per year was assessed using the slope of
eGFR obtained from a generalized linear mixed model. The
statistical analyses were performed using Stata, version 15.1 (Stata
Corporation, College Station, TX). A p < 0.05 was considered
statistically significant.
RESULTS
Baseline Characteristics Among Three
Trajectories of BMI
Table 1 presents the baseline characteristics of the participants
according to the trajectories of changes in BMI. During the BMI
assessment period, BMI decreased to −7.5% from the baseline
in the decreasing BMI group, whereas it increased to 7.6% from
the baseline in the increasing BMI group. The difference in
BMI and the percent changes of BMI remained constant after
the BMI assessment period (Supplementary Table 2). The 5,393
participants included 2,636 (48.9%) men, and the mean (SD) age
was 50.8 (8.5) years. The baseline BMI was significantly lower
in the increasing BMI group than in the stable and decreasing
groups. The increasing BMI group had a lower proportion of
obese participants and lower levels of baseline BP, fasting glucose,
insulin resistance, total cholesterol, triglyceride, and hs-CRP
levels. On the contrary, the baseline eGFR and HDL-cholesterol
levels were significantly higher in the increasing BMI group
than in the decreasing group. MMI and FMI were lower in the
increasing BMI group. However, the MF ratio was significantly
higher in the increasing BMI group compared with the stable and
decreasing BMI group.
Risk of Incident Chronic Kidney Disease
During 55,327 person-years (median 11.5 years), incident CKD
occurred in 354 (6.5%) participants, and the overall CKD
incidence rate was 6.3 per 1,000 person-years. Among three
trajectory groups, the incidence rates of CKD were 6, 6.1, and
7.8 per 1,000 person-years in decreasing, stable, and increasing
trajectory groups, respectively (P = 0.005). The unadjusted
HRs did not differ among groups (Model 1). However, in the
multivariable Cox proportional hazard model after sequential
adjustment of demographics and repeated laboratory measures,
the HR for incident CKD was 1.39 (95% CI 1.04–1.86) in the
increasing BMI group compared with the stable group (Model
3). In the model, further adjusted for metabolic parameters
such as HDL-C, triglyceride, and hs-CRP, the increasing BMI
group had a 1.45-fold (HR, 1.45; 95% CI, 1.08–1.94) higher
risk of CKD development compared with the stable group
(Table 2). In addition, the decreasing BMI group had a 39%
(HR,0.61; 95% CI,0.41–0.89; P = 0.01) lower risk of CKD
development when compared with the increasing BMI group
(Supplementary Table 3). In the adjusted Kaplan-Meier plot,
the cumulative incidence of CKD development was significantly
higher in the increasing BMI group (Supplementary Figure 2).
In sensitivity analysis with an outcome assessment period of years
4–8, the HR was 1.63 (95% CI, 1.15–2.31) in the increasing BMI
group compared with the stable group (Supplementary Table 4).
In additional sensitivity analysis after excluding 534 subjects with
isolated microscopic hematuria, increasing BMI trajectory also
showed a higher risk of incident CKD than stable trajectory
(HR 1.39, 95% CI, 1.03–1.91) (Supplementary Table 5). The
restricted cubic spline curve after full adjustment of confounding
factors also showed a graded increase in HRs in proportion to
changes in BMI (Figure 2). Finally, the slope of eGFR decline
per year [ml/min/1.73 m2 (95% CI)] was significantly greater
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FIGURE 3 | Multivariable-adjusted hazard ratios for CKD developments according to trajectories, stratified by subgroups. Each HR and 95% CI were expressed after
adjustment of covariates, including age, sex, the area of residence, smoking, alcohol consumption habit, income, education levels, body mass index, mean arterial
pressure, hemoglobin, albumin, fasting glucose, estimated glomerular filtration rate, high-density lipoprotein-cholesterol, triglyceride, and high-sensitive C-reactive
protein. BMI, body mass index; No, number; CKD, chronic kidney disease; HR, hazard ratio; CI, confidence interval.
in the increasing BMI trajectory [−1.28 (−1.42 to −1.15)]
compared with stable trajectory [−1.01 (−1.09 to −0.97)]
(Supplementary Table 6).
Subgroup Analysis
We also tested the effects of weight change on incident CKD
in prespecified groups. An increased risk of CKD development
associated with an increase in BMI was observed in most
subgroups (Figure 3). Notably, this association was particularly
evident in the overweight (HR, 1.61; 95% CI, 1.05–2.47) and
obese (HR, 2.21; 95%CI, 1.40–3.48) participants, and the harmful
association of weight gain was not observed in the normal
weight group.
Changes in Metabolic Profile Parameters
We further examined longitudinal changes in BP, insulin
resistance, lipid profiles, and an inflammatory marker over time.
The BMI changes correlated positively with changes inMAP, total
cholesterol, and triglyceride levels, and inversely correlated with
changes in the HDL-cholesterol level (Supplementary Table 7).
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FIGURE 4 | Longitudinal changes in the MAP, HOMA-IR, and metabolic profiles across the trajectories. Cumulative averaged values of MAP, HOM-IR, lipid profiles,
and hs-CRP were calculated as the mean of measurements of each parameter during the follow-up period. MAP, mean arterial pressure; HOMA-IR, homeostasis
model assessment for insulin resistance; HDL-C, high-density lipoprotein-cholesterol; hs-CRP, high-sensitive C-reactive protein.
These parameters were significantly worsened over time along
with increasing BMI (P-for-trend <0.001). Moreover, despite the
initial better metabolic profiles and lower inflammation in the
increasing BMI group up to year 2, these favorable features were
notably lost from year 4, and this group had persistently higher
levels of MAP, insulin resistance, total cholesterol, triglycerides,
and hs-CRP thereafter (Figure 4).
Changes in Muscle, Fat, and Muscle-to-Fat
Ratios
Finally, changes in body composition were compared across
three trajectories. Muscle mass did not differ among BMI
groups throughout the follow-up period. At the baseline, FMI
was higher in the decreasing BMI group than in the stable
and increasing groups. However, this pattern was reversed
from year 2. FMI increased from 15 to 18.2 in the increasing
BMI group but decreased from 19.2 to 16.9 in the decreasing
group at year 2. FMI remained persistently higher in the
increasing BMI group thereafter. Accordingly, the direction of
the changes in FMI was the opposite to that of the MMI/FMI
ratio (Supplementary Table 8). These changes over time are
presented using cumulative averaged means of the MMI, FMI,
and MMI/FMI ratio in Figure 5.
DISCUSSION
The present study showed that weight gain was significantly
associated with a higher risk of incident CKD in healthy
individuals without comorbidities. This association was
attributed to an increase in BP and deterioration of metabolic
profiles over time, which were also accompanied by an increase
in fat mass and a decrease in the MF ratio, following weight
gain. Our findings are noteworthy because we provided in-depth
analysis with a special interest in the harmful association of
weight gain on kidney disease for long-term observation. This
study also highlights the importance of lifestyle modifications to
prevent CKD development.
Obesity is an established risk factor for cardiovascular events,
stroke, diabetes, and cancer, and is a significant predictor of CKD
in the general population (27–30). Although obesity is known as a
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FIGURE 5 | Longitudinal changes in the MMI, FMI, and MF ratio across the trajectories. Cumulative averaged values of the MMI, FMI, and MF ratio were calculated as
the mean of measurements of each parameter during the follow-up period. MMI, muscle mass index; FMI, fat mass index; MF, muscle to fat.
modifiable factor, it is very difficult tomaintain body weight at the
optimal level after an intended weight loss. Moreover, regaining
weight commonly occurs despite the lifestyle modification with
diet and exercise, which can lead to uncertain effects of weight
reduction on outcomes. Such a weight-regain phenomenon has
recently been documented in the Look Action for Health in
Diabetes (AHEAD) study. In this trial, with intensive lifestyle
intervention, cardiovascular events, and death in overweight and
obese adults with type 2 diabetes did not improve following
weight loss (31). However, before the occurrence of weight regain
that was obviously observed after 1 year, modest weight loss was
associated with significant improvements in BP, glycemic status,
and lipid profile, suggesting the necessity for long-term sustained
weight loss to see the benefits (32). In this regard, our trajectory
analysis has some merits because this method well-disclosed the
trends in BMI changes over time, which allowed us to explore the
long-term association of weight changes with incident CKD.
The mechanisms underlying the interaction between weight
gain and CKD development remain largely presumptive. Ryu
et al. postulated that what the subjects experienced may have
been caused by worsening cardiovascular or metabolic risk and
that they, therefore, had an increased risk of CKD (33). However,
these studies did not show concomitant changes in the metabolic
profiles of the subjects. In this study, we clearly showed the
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concomitant worsening of BP, insulin resistance, inflammation,
and lipid profiles along with weight gain. It can be presumed that
such metabolic derangements adversely affect kidney function.
Despite concerns about the inability of BMI to distinguish fat and
muscle mass, BMI is highly correlated with adiposity (34), and
both increasing weight and body fat carry metabolic risk (35, 36).
In our study with body composition analysis, increased BMI was
accompanied by decreased MMI and increased FMI, resulting
in decreased MF ratios. These changes in body composition
toward unhealthy conditions can cause chronic inflammation
and negative metabolic effects (37, 38) and lead to structural
damage to the kidney and decline in kidney function (39). Thus,
our long-term observation on the changes in metabolic profiles,
inflammation, and body fat mass can support the link between
obesity and CKD.
In contrast to the significantly higher association of weight
gain with risk of incident CKD, we did not show that weight
loss was not associated with a lower risk of CKD development.
Notably, the individuals in the decreasing BMI group were
more obese (60.5%) and had unfavorable features of BP, insulin
resistance, lipid profiles, and body composition at the baseline
compared with the stable and increasing BMI groups. These
residual harmful effects of obesity and metabolic abnormalities
in the decreasing BMI group might dilute the beneficial effect
of weight loss. In addition, the BMI trajectory assessment period
was 4 years. Although the unfavorable metabolic parameters were
improved during this period, it would take a longer time to
exert the clinical benefits of weight loss on CKD development.
Nevertheless, when the risk was compared with the increasing
BMI group, the decreasing BMI group had a 39% lower risk of
incident CKD, suggesting a positive aspect of weight loss against
weight gain.
This study has some strengths. To assess the significance of
the weight gain itself, we applied strict exclusion criteria; thus,
only healthy individuals without comorbidities were included.
The use of trajectory analysis is another strength because this
method can accurately identify groups with similar trends of
changes in BMI over time. Moreover, to avoid the chance of
bias due to reversal causality, we analyzed only adverse kidney
events that occurred after the BMI trajectory assessment period.
Lastly, the KoGES cohort comprises relatively homogenous
individuals with a single ethnic group who had undergone
extensive assessments for 10 years. This long-term observation
period with serial measurements enabled us to comprehensively
analyze the associations between CKD development and changes
in body weight, metabolic profiles, and body composition.
Several limitations should be also discussed. First, the
causal relationship between weight gain and increased risk of
CKD development could not fully be established due to the
observational study design. Despite the rigorous adjustment,
residual confounding is likely to exist in our analyses. Second,
BMI has intrinsic problems because it cannot distinguish between
muscle and fat, visceral and subcutaneous fat, or peripheral
and central adiposity. To minimize this limitation of BMI, we
also measured fat and muscle contents by multifrequency BIA
and showed that changes in BMI were concomitant to those in
muscle and fat mass index. Future studies need more accurate
body composition measurements such as dual-energy X-ray
absorptiometry to address this issue. Third, the study cohort
included asymptomatic middle-aged Korean adults; thus, our
findings may not be generalizable to other ethnic groups.
CONCLUSION
In conclusion, weight gain was associated with an increased
risk of incident chronic kidney disease (CKD) in healthy
individuals without comorbid conditions. This relationship was
stronger for overweight and obese subjects. An increase in
BP and deterioration in metabolic profiles accompanied by
increased fat mass may explain the harmful association of weight
gain with CKD development. Our findings warn against the
potential hazards of weight gain over time on the adverse kidney
outcome. More well-designed trials with intensive interventions
should address whether weight control can protect against
kidney injury.
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